Notes on Fatty Acids, Ketogenesis and Diabetic Ketoacidosis

Pathophysiology of Diabetic Ketoacidosis (DKA)

Diabetic ketoacidosis is presented as an acute complication of type 1 diabetes characterized by insulin deficiency in the setting of relatively elevated counter-regulatory hormones, including glucagon. The trigger for DKA can be diverse: stopping insulin therapy, never initiating insulin, or situations that elevate counter-regulatory hormones such as infection, surgery, anesthesia, and, more recently, fasting in the context of SGLT2 inhibitors. The resulting metabolic picture features hyperglycemia because of increased hepatic gluconeogenesis and glucose output and, at the same time, decreased peripheral glucose utilization due to lack of insulin. In uncontrolled DKA, there is accelerated lipolysis with breakdown of adipose triglycerides (triglycerides) into glycerol and free fatty acids (FFAs). FFAs are released into the plasma and bind non-covalently to albumin. They are then taken up by hepatocytes, imported into mitochondria, and oxidized via beta-oxidation to generate acetyl-CoA (a two-carbon unit).

A key biochemical shift occurs because gluconeogenesis is strongly activated in insulin deficiency, consuming oxaloacetate and other substrates of the citric acid cycle to produce glucose. This diversion reduces the turnover of the citric acid cycle, so acetyl-CoA from fatty acid oxidation cannot effectively enter the cycle. As a result, acetyl-CoA is redirected into ketone body synthesis, leading to an accumulation of ketone bodies in the plasma and the development of ketoacidosis.

In this setting, the hormonal milieu is characterized by decreased insulin and increased glucagon, along with other counter-regulatory hormones, all of which worsen lipolysis, gluconeogenesis, and ketogenesis. Fat cell triglycerides are broken down, causing plasma free fatty acids to rise. These FFAs are taken up by hepatocytes, transported into mitochondria, and oxidized to acetyl-CoA. Because gluconeogenesis consumes oxaloacetate and other tricarboxylic acid (TCA) cycle intermediates, the TCA cycle cannot effectively turnover acetyl-CoA, so acetyl-CoA is diverted toward ketone body synthesis. The resulting surge in ketone bodies—principally beta-hydroxybutyrate (BHB) and acetoacetate—produces an accumulation of protons through glycerol breakdown and fatty acid oxidation, contributing to metabolic acidosis (ketoacidosis).

In clinical data, arterial or venous blood gas analysis demonstrates a metabolic acidosis with a low pH and a low bicarbonate. Normal blood pH is about pH≈7.40pH \approx 7.40. In DKA, the pH typically falls to the range of pH∈[7.0,7.2]pH \in [7.0, 7.2]. The bicarbonate (HCO$3^-$) is markedly reduced, typically well below [HCO3^-] < 10\ \mathrm{mmol/L}, whereas the normal range is approximately [HCO3−]≈25−30 mmol/L[HCO_3^-] \approx 25{-}30\ \mathrm{mmol/L}. Ketone bodies rise in plasma due to accelerated ketogenesis: the beta-hydroxybutyrate (BHB) level normally is less than [\beta{-}\text{hydroxybutyrate}] < 0.3\ \mathrm{mmol/L}, but in DKA it becomes markedly elevated, up to about [β−hydroxybutyrate]≈10−15 mmol/L[\beta{-}\text{hydroxybutyrate}] \approx 10{-}15\ \mathrm{mmol/L}. Acetoacetate levels also rise, but typically at about one third of the BHB levels, i.e. [acetoacetate]≈13 [β−hydroxybutyrate]in DKA[\text{acetoacetate}] \approx \frac{1}{3}\,[\beta{-}\text{hydroxybutyrate}] \quad \text{in DKA}.

Potassium balance in DKA shows initial hyperkalemia in many patients. Plasma potassium is often elevated early, which reflects the acidosis and impaired Na^+/K^+-ATPase activity, causing a shift of potassium from cells into the extracellular space. This creates a dangerous situation because high plasma potassium can predispose to cardiac arrhythmias. As treatment proceeds—with rehydration, insulin administration, and correction of metabolic abnormalities—plasma potassium frequently falls as potassium shifts back into cells and renal excretion increases, potentially leading to hypokalemia if not carefully managed. Therefore, management requires careful potassium monitoring and replacement in parallel with insulin therapy.

In terms of pathophysiology, the following sequence is central: decreased insulin and increased glucagon and counter-regulatory hormones drive adipose triglyceride breakdown, releasing free fatty acids which circulate bound to albumin. These FFAs are imported into hepatocyte mitochondria and oxidized to acetyl-CoA; because oxaloacetate is diverted to gluconeogenesis, acetyl-CoA cannot efficiently enter the citric acid cycle, so it is redirected to ketogenesis, producing ketone bodies and protons, thereby causing acidosis. This sequence explains the metabolic features of DKA: hyperglycemia, ketonemia, metabolic acidosis, dehydration, and electrolyte disturbances. The clinical picture is often complemented by associated dehydration and polyuria due to high plasma glucose and osmotic diuresis. Finally, the lecture notes emphasize that this four-lecture series has highlighted fatty acids as a major energy source, triglycerides as an energy store, and the link between dietary fat, adipose triglycerides, fatty acid oxidation, and ketone body formation during DKA. The speaker also notes potential triggers such as infection, surgery, anesthesia, and SGLT2 inhibitors in fasting states, and concludes by pointing to papers for further reading.

Biochemical Pathways and Ketogenesis in Detail

A central biochemical pathway is fatty acid oxidation within mitochondria. Free fatty acids (FFAs) released from adipose tissue are taken up by hepatocytes and transported into mitochondria where beta-oxidation yields acetyl-CoA. In the context of insulin deficiency, gluconeogenesis is upregulated and oxaloacetate is diverted away from the citric acid cycle to generate glucose. This diversion reduces the availability of CAC intermediates, effectively throttling the cycle and preventing acetyl-CoA from entering the cycle. The consequence is that acetyl-CoA is redirected toward ketogenesis, forming ketone bodies including acetoacetate and beta-hydroxybutyrate. A simplified representation of ketogenesis is as follows: 2\ ext{acetyl-CoA} \rightarrow \text{acetoacetyl-CoA} \rightarrow \text{HMG-CoA} \rightarrow \text{acetoacetate} \,+\, \beta{-}\text{hydroxybutyrate} \n

Beta-hydroxybutyrate and acetoacetate are the principal circulating ketone bodies in DKA; their accumulation lowers blood pH, contributing to the metabolic acidosis. In addition to ketogenesis, glycerol released from triglyceride breakdown can be oxidized, generating protons and contributing to acidosis through additional hydrogen ion production. FFAs and glycerol thus contribute to both the energy deficit and the acid–base disturbance that characterizes DKA. In parallel, the hyperglycemia drives osmotic diuresis, leading to dehydration and further concentration of plasma solutes.

The presentation of laboratory data in the lecture underscores the metabolic state: metabolic acidosis with low pH and low bicarbonate, marked ketonemia with elevated BHB and acetoacetate, and potassium imbalance with an early rise in plasma potassium followed by potential depletion during treatment if not properly managed. The interplay among insulin, glucagon, cortisol, catecholamines, and other counter-regulatory hormones drives lipolysis, gluconeogenesis, and ketogenesis, and explains why management must address both glucose control and electrolyte balance.

Clinical Data and Laboratory Findings (ABG and Biochemistry)

Arterial or venous blood gas data in DKA show a metabolic acidosis with a reduced pH. The typical range for pH in DKA is pH∈[7.0,7.2]pH \in [7.0, 7.2], with the normal value around pH≈7.40pH \approx 7.40. The bicarbonate concentration falls markedly, with normal values near [HCO3−]≈25−30 mmol/L[HCO_3^-] \approx 25{-}30\ \mathrm{mmol/L} but in DKA the bicarbonate is typically less than 10 mmol/L10\ \mathrm{mmol/L}. The ketone bodies are elevated in plasma due to increased synthesis: [β−hydroxybutyrate]≫0.3 mmol/L[\beta{-}\text{hydroxybutyrate}] \gg 0.3\ \mathrm{mmol/L}, often reaching between 10 to 15 mmol/L10\text{ to }15\ \mathrm{mmol/L} in DKA. Acetoacetate also rises, but its level is typically about one third of the BHB level, i.e. [acetoacetate]≈13 [β−hydroxybutyrate][\text{acetoacetate}] \approx \frac{1}{3}\,[\beta{-}\text{hydroxybutyrate}].

Plasma potassium is notable for its dynamic changes. It is commonly elevated early in DKA due to a shift of potassium out of cells in the acidic milieu and the impairment of the sodium–potassium ATPase pump. The elevated potassium can predispose to dangerous arrhythmias. However, as treatment begins—rehydration, insulin therapy, and correction of the metabolic state—potassium tends to fall as it is driven back into cells and is excreted in the urine. This necessitates close monitoring of potassium levels and timely potassium replacement to prevent iatrogenic hypokalemia during insulin therapy.

These laboratory features reflect the underlying pathophysiology: a state of insulin deficiency with glucagon excess leading to hyperglycemia, fatty acid mobilization, hepatic ketogenesis, and a consequential metabolic acidosis driven by ketone bodies and proton generation from glycerol and fatty acid oxidation. Clinically, dehydration from osmotic diuresis accompanies these changes, reinforcing the need for timely rehydration.

Management Principles and Clinical Care Implications

The management of DKA centers on three interrelated pillars: rehydration, insulin therapy, and electrolyte management, with careful monitoring for infectious triggers or complications. Rehydration typically begins with intravenous normal saline to restore circulating volume and improve tissue perfusion, which also helps in correcting renal function and enabling better clearance of ketones and glucose. Insulin therapy is then employed to suppress lipolysis and ketogenesis, reduce hepatic glucose output, and promote cellular glucose uptake. The administration of insulin must be balanced with electrolyte management, particularly potassium, because insulin drives potassium into cells and can precipitate life-threatening hypokalemia if potassium replacement is not concurrently adjusted. Therefore, potassium levels are closely monitored and potassium is replaced as necessary to maintain a safe plasma level.

In addition to the core treatment, clinicians should search for and address precipitating factors. Infection is a common trigger for DKA; the patient should be evaluated for pneumonia, pyelonephritis, and other infections, with appropriate antibiotic therapy when indicated. The transcript notes that infections or other problems should be treated as appropriate, and highlights that SGLT2 inhibitors in the setting of fasting can contribute to DKA risk, underscoring the need for awareness of patient medication history during management.

Across these lectures, the overarching message is that fatty acids are a major energy source in DKA, triglycerides serve as a large reservoir of fatty acids, and during DKA there is accelerated lipolysis releasing fatty acids that are oxidized to acetyl-CoA. Because gluconeogenesis consumes oxaloacetate, the citric acid cycle slows, acetyl-CoA is diverted to ketone bodies, and a state of metabolic acidosis ensues due to ketone body production and proton generation. The presenter notes that several papers are available for further reading to expand on these concepts.

Connections to Fatty Acid Metabolism, Physiology, and Real-World Relevance

This set of lectures connects fatty acid metabolism to clinical pathology by tracing how adipose triglycerides break down under insulin deficiency, liberating free fatty acids that are transported to the liver and converted into acetyl-CoA. The lack of insulin and the presence of high glucagon levels switch on gluconeogenesis, which in turn depletes oxaloacetate and limits TCA cycle flux. Consequently, acetyl-CoA is redirected toward ketogenesis, increasing circulating ketone bodies and causing metabolic acidosis. The clinical manifestations—hyperglycemia, dehydration from polyuria, electrolyte disturbances, particularly potassium abnormalities—emerge from this metabolic cascade. The notes also emphasize that clinical triggers include infection, surgery, anesthesia, and, in fasting states, SGLT2 inhibitors as contributing factors. The management strategy—rehydration, insulin therapy, electrolyte monitoring and replacement, and infection control—addresses the key metabolic derangements and the potential complications such as dangerous arrhythmias from hyperkalemia. The discussion reinforces the practical relevance of understanding fatty acid stores, triglyceride metabolism, and ketogenic pathways in diagnosing and treating DKA, and it suggests reading papers for further depth.

Summary Takeaways and Practical Implications

  • Fatty acids from adipose tissue become the primary energy source during DKA due to insulin deficiency and glucagon excess.

  • Triglycerides serve as large stores of fatty acids, which are mobilized during DKA and enter hepatic beta-oxidation to form acetyl-CoA.

  • Gluconeogenesis is upregulated, consuming oxaloacetate and other CAC intermediates, leading to reduced CAC turnover and diversion of acetyl-CoA to ketone body synthesis.

  • Ketone bodies, specifically beta-hydroxybutyrate and acetoacetate, accumulate in plasma and cause metabolic acidosis. The normal beta-hydroxybutyrate level is < 0.3 mmol/L0.3\ \mathrm{mmol/L}, but in DKA it can reach ≈10−15 mmol/L\approx 10{-}15\ \mathrm{mmol/L}; acetoacetate rises as well, typically about one third of BHB levels in DKA.

  • pH is generally depressed (pH∈[7.0,7.2]pH \in [7.0, 7.2]) with low bicarbonate (normal [HCO<em>3−]≈25−30 mmol/L[HCO<em>3^-] \approx 25{-}30\ \mathrm{mmol/L}, usually [HCO3^-] < 10\ \mathrm{mmol/L} in DKA).

  • Plasma potassium may be high initially due to acidosis and Na^+/K^+-ATPase impairment, but tends to fall during treatment as insulin is given and kidneys excrete potassium; this necessitates careful monitoring and replacement to prevent hypokalemia.

  • Management revolves around rehydration (often IV normal saline), insulin therapy to correct hyperglycemia and suppress ketogenesis, potassium management, and addressing precipitating factors such as infection. Awareness of SGLT2 inhibitors and fasting as potential triggers is important for prevention and early recognition.

  • The content ties Fatty Acid Metabolism to clinical practice and provides a coherent model of how dysregulated energy metabolism leads to DKA, highlighting the practical steps clinicians take to reverse the metabolic catastrophe and prevent complications.

Papers and further readings are suggested by the lecturer as useful resources for expanding on these concepts.